Larazotide

Larazotide (also known as Larazotide acetate, AT-1001, INN-202) is a prominently researched experimental compound classified strictly within the Zonulin Antagonist framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it synthetic octapeptide that acts as a zonulin antagonist. Zonulin is the body's primary regulator of intestinal tight junction permeability; elevated zonulin (triggered by gliadin/gluten and dysbiosis) opens tight junctions and causes intestinal permeability ('leaky gut'). Larazotide competitively blocks zonulin receptor binding, preventing tight junction opening and reducing gut permeability without systemic absorption. with a documented biological half-life of roughly 1.5 hours, In preclinical investigative trials and independent academic studies, researchers utilizing Larazotide have documented significant, quantifiable biological outcomes, primarily focusing on gut barrier repair, tight junction integrity, celiac disease symptom reduction, leaky gut. Typical research protocols investigate administering 500 to 500mcg via oral pathways 3x daily (with meals). However, it is critically important to understand that while Larazotide demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.